Teleflex Incorporated (NYSE:TFX) Short Interest Down 37.1% in April

Teleflex Incorporated (NYSE:TFX) saw a significant decrease in short interest in April. As of April 15th, there was short interest totalling 1,560,000 shares, a decrease of 37.1% from the March 31st total of 2,480,000 shares. Approximately 3.5% of the shares of the stock are sold short. Based on an average daily volume of 1,140,000 shares, the days-to-cover ratio is currently 1.4 days.

Institutional Trading of Teleflex

A number of institutional investors have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Teleflex by 4.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,173,121 shares of the medical technology company’s stock valued at $1,098,693,000 after buying an additional 261,279 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Teleflex by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 1,138,867 shares of the medical technology company’s stock worth $202,161,000 after buying an additional 8,307 shares during the period. Cooke & Bieler LP grew its holdings in shares of Teleflex by 22.1% during the fourth quarter. Cooke & Bieler LP now owns 1,078,557 shares of the medical technology company’s stock valued at $191,962,000 after buying an additional 195,150 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Teleflex by 48.1% during the fourth quarter. Invesco Ltd. now owns 1,068,593 shares of the medical technology company’s stock valued at $190,188,000 after buying an additional 347,003 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its holdings in shares of Teleflex by 38.1% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 590,529 shares of the medical technology company’s stock valued at $105,102,000 after buying an additional 162,950 shares during the last quarter. 95.62% of the stock is currently owned by institutional investors.

Teleflex Trading Down 0.4 %

NYSE TFX opened at $134.69 on Tuesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42. The company has a market capitalization of $6.25 billion, a price-to-earnings ratio of 26.78, a price-to-earnings-growth ratio of 1.73 and a beta of 1.19. The company’s 50-day simple moving average is $139.36 and its two-hundred day simple moving average is $172.78. Teleflex has a one year low of $124.66 and a one year high of $249.91.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, February 27th. The medical technology company reported $3.89 EPS for the quarter, beating analysts’ consensus estimates of $3.86 by $0.03. The business had revenue of $795.40 million for the quarter, compared to the consensus estimate of $813.24 million. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. Equities analysts forecast that Teleflex will post 13.98 EPS for the current fiscal year.

Teleflex Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 17th. Stockholders of record on Friday, March 7th were issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.01%. The ex-dividend date of this dividend was Friday, March 7th. Teleflex’s dividend payout ratio is currently 95.77%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on TFX shares. Royal Bank of Canada downgraded shares of Teleflex from an “outperform” rating to a “sector perform” rating and decreased their price target for the company from $220.00 to $155.00 in a research note on Friday, February 28th. Piper Sandler reissued a “neutral” rating and issued a $140.00 target price (down previously from $255.00) on shares of Teleflex in a research note on Friday, February 28th. StockNews.com downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. Wells Fargo & Company reduced their target price on shares of Teleflex from $214.00 to $146.00 and set an “equal weight” rating on the stock in a research note on Friday, February 28th. Finally, Citizens Jmp downgraded shares of Teleflex from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $169.63.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.